[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA cancer J clin, 2021, 71(3): 209-249.
[2] Yang Y, Gao Z, Huang A, et al.Epidemiology and early screening strategies for colorectal cancer in China[J]. Chin J Cancer Res, 2023, 35(6): 606-617.
[3] Biller LH, Schrag D.Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review[J]. JAMA, 2021, 325(7): 669-685.
[4] Xin P, Xu X, Deng C, et al.The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol, 2020, 80: 106210.
[5] Li YJ, Zhang C, Martincuks A, Herrmann A, et al.STAT proteins in cancer: orchestration of metabolism[J]. Nat Rev Cancer, 2023, 23(3): 115-134.
[6] Hu X, Li J, Fu M, et al.The JAK/STAT signaling pathway: from bench to clinic[J]. Signal Transduct Target Ther, 2021, 6(1):402.
[7] Underwood PW, Ruff SM, Pawlik TM.Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer[J]. Cells, 2024, 13(3): 245.
[8] Müller M, Laxton C, Briscoe J, et al.Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and-gamma signal transduction pathways[J]. Embo J, 1993, 12(11): 4221-4228.
[9] Owen KL, Brockwell NK, Parker BS.JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression[J]. Cancers (Basel), 2019, 11(12): 2002.
[10] Kohanbash G, Okada H.MicroRNAs and STAT interplay[J]. Semin Cancer Biol, 2012, 22(1): 70-75.
[11] O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3): 151-167.
[12] Meissl K, Macho-Maschler S, Müller M, et al.The good and the bad faces of STAT1 in solid tumours[J]. Cytokine, 2017, 89: 12-20.
[13] Lee CK, Rao DT, Gertner R, et al.Distinct requirements for IFNs and STAT1 in NK cell function[J]. J Immunol, 2000, 165(7): 3571-3577.
[14] Putz EM, Gotthardt D, Hoermann G, et al.CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance[J]. Cell Rep, 2013, 4(3): 437-444.
[15] Sasidharan NV, Toor SM, Ali BR, et al.Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells[J]. Expert Opin Ther Targets, 2018, 22(6): 547-557.
[16] Bellucci R, Martin A, Bommarito D, et al.Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression[J]. Oncoimmunology, 2015, 4(6): e1008824.
[17] Liu J, Hamrouni A, Wolowiec D, et al.Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway[J]. Blood, 2007, 110(1): 296-304.
[18] Han Y, Zhang Y, Tian Y, et al.The Interaction of the IFNγ/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells[J]. J Oncol, 2022, 2022: 9016296.
[19] Su YC, Chen YC, Tseng YL, et al.The Pro-Survival Oct4/Stat1/Mcl-1 Axis Is Associated with Poor Prognosis in Lung Adenocarcinoma Patients[J]. Cells, 2021, 10(10): 2642.
[20] Wong GL, Manore SG, Doheny DL, et al.STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges[J]. Semin Cancer Biol, 2022, 86(Pt 3): 84-106.
[21] Koromilas AE, Sexl V.The tumor suppressor function of STAT1 in breast cancer[J]. JAKSTAT, 2013, 2(2): e23353.
[22] Tang T, Huang X, Lu M, et al.Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and-autocrine manner[J]. Nat Commun, 2023, 14(1): 3364.
[23] Zhang X, Li X, Tan F, et al.STAT1 Inhibits MiR-181a Expression to Suppress Colorectal Cancer Cell Proliferation Through PTEN/Akt[J]. J Cell Biochem, 2017, 118(10): 3435-3443.
[24] Stempelj M, Kedinger M, Augenlicht L, et al.Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate[J]. J Biol Chem, 2007, 282(13): 9797-9804.
[25] Tanaka A, Zhou Y, Ogawa M, et al.STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability[J]. PLoS One, 2020, 15(4): e0229252.
[26] Kikuchi T, Mimura K, Okayama H, et al.A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ[J]. Oncol Lett, 2019, 18(6): 5977-5985.
[27] Wang S, Darini C, Désaubry L, et al.STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A[J]. Mol Cancer Ther, 2016, 15(12): 3055-3063.
[28] Chou PH, Luo CK, Wali N, et al.A chemical probe inhibitor targeting STAT1 restricts cancer stem cell traits and angiogenesis in colorectal cancer[J]. J Biomed Sci, 2022, 29(1): 20.
[29] Lao VV, Grady WM.Epigenetics and colorectal cancer[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(12): 686-700.
[30] Leon-Cabrera S, Vázquez-Sandoval A, Molina-Guzman E, et al.Deficiency in STAT1 Signaling Predisposes Gut Inflammation and Prompts Colorectal Cancer Development[J]. Cancers (Basel), 2018, 10(9): 341.
[31] Yu L, Ye F, Li YY, et al.Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 axis[J]. Carcinogenesis, 2020, 41(5): 678-688.
[32] Ji D, Feng Y, Peng W, et al.NMI promotes cell proliferation through TGFβ/Smad pathway by upregulating STAT1 in colorectal cancer[J]. J Cell Physiol, 2020, 235(1): 429-441.
[33] Li X, Chen X, Gong S, et al.Platelets promote CRC by activating the C5a/C5aR1 axis via PSGL-1/JNK/STAT1 signaling in tumor-associated macrophages[J]. Theranostics, 2023, 13(6): 2040-2056.
[34] Delgado-Ramirez Y, Baltazar-Perez I, Martinez Y, et al.STAT1 Is Required for Decreasing Accumulation of Granulocytic Cells via IL-17 during Initial Steps of Colitis-Associated Cancer[J]. Int J Mol Sci, 2021, 22(14): 7695.
[35] David M, Naudin C, Letourneur M, et al.Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells[J]. Mol Oncol, 2014, 8(5): 942-955.
[36] Letellier E, Schmitz M, Baig K, et al.Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer[J]. Br J Cancer, 2014, 111(4): 726-735.
[37] Shuai K.Regulation of cytokine signaling pathways by PIAS proteins[J]. Cell Res, 2006, 16(2): 196-202.
[38] Munarriz E, Barcaroli D, Stephanou A, et al.PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73[J]. Mol Cell Biol, 2004, 24(24): 10593-10610.
[39] Hoekstra E, Peppelenbosch MP, Fuhler GM.The role of protein tyrosine phosphatases in colorectal cancer[J]. Biochim Biophys Acta, 2012, 1826(1): 179-188.
[40] Li X, Wang Z, Zhang S, et al.Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis[J]. Oncol Lett, 2021, 21(5): 352.
[41] Yin Y, Liu B, Cao Y, et al.Colorectal Cancer-Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD-L1 Expression in Tumor-Associated Macrophages[J]. Adv Sci (Weinh), 2022, 9(9): 2102620.
[42] Wang H, Zhou Y, Zhang Y, et al.Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target[J]. J Immunother Cancer, 2022, 10(4): e004302.
[43] Shang S, Yang C, Chen F, et al.ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer[J]. Nat Commun, 2023, 14(1): 7661.
[44] Wen Y, Ye S, Li Z, et al.HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy[J]. Cancer Immunol Immunother, 2024, 73(1): 7.
[45] Zhang Y, Tao Y, Gu Y, et al.Butyrate facilitates immune clearance of colorectal cancer cells by suppressing STAT1-mediated PD-L1 expression[J]. Clinics (Sao Paulo), 2023, 78: 100303. |
